Answers are grounded in this paper and cite their sources.
Reviews evidence on hemoglobin-based oxygen carriers and perfluorocarbons, indicating their potential as temporary resuscitation alternatives when blood products are unavailable.
This Military Supplement to Shock highlights the state of the science on oxygen carrier solutions that was the focus of a DoD Combat Casualty Care Research Program meeting held in February 2017. In anticipation of military preparation of its medical capabilities to meet the needs on future battlefields, projected to be more complex and quite different than the conditions experienced in the recent conflicts in Iraq and Afghanistan, the meeting reviewed the current state of hemoglobin-based oxygen carriers (HBOC) and perfluorocarbons (PFC) and lessons learned from previous clinical trials with these products. Despite the push by the military to get more blood products, including low titer type O whole blood, closer to the point-of-injury, it is recognized that logistic constraints will limit the availability of blood products on the battlefield. In addition, the military anticipates future military operations occurring in multidomain battlespaces, which presents medical challenges associated with prolonged care, that is, care beyond the current golden hour and the usual time to hold a casualty based on the injury. These scenarios present significant challenges to providing state-of-the-art medical care for resuscitation of injured servicemembers. To address this anticipated medical need, the military is again exploring the possibilities of employing solutions that carry oxygen as resuscitation alternatives when blood products or whole blood is not available or an option. Thus, this Shock Supplement presents eight papers on HBOCs, seven on PFCs, and one paper describing a possible interdisciplinary approach for designing more robust clinical trials for future evaluation of these products. Three reviews examine the basic chemistry and design of HBOCs and challenges regarding their development. An ideal HBOC would deliver oxygen to tissue efficiently, require no special storage conditions, have a long shelf life, low toxicity, and be manufactured in high yields and have a low cost. Gupta (1) provides a comprehensive analysis of the various designs of HBOC molecules that have been developed over the years and the potential advantages and limitations of each product. In addition, the choice of chemically modified cell-free hemoglobin or an encapsulated product, and the source of the hemoglobin molecule, including recombinant forms, are discussed with regard to manufacturing challenges and clinical efficacy and safety. The review by Alayash (2) also mentions the various forms of current and previously developed HBOCs and along with that of Benitez-Cardenas (3) focuses mainly on the mechanisms associated with HBOC toxicity. All three reviews discuss some of the newer HBOCs under development and the approaches to reduce their side effects, including use of protein engineering techniques. One of the newer HBOCs is Sanguinate, a bovine PEGylated carboxyhemoglobin molecule with a CO moiety to maintain microvascular perfusion. In a preclinical study of hemorrhagic shock in rats, Nugent et al. (4) describe that Sanguinate improved survival time, MAP, and tissue oxygenation better than similar doses of lactated Ringer's or the colloid, Hextend. HBOCs have been evaluated in several clinical trials, primarily as a ‘blood substitute,’ comparing them with red blood cells. The review by Mackenzie et al. (5) summarizes the previous experiences from 1,701 clinical uses of HBOC-201, a polymerized bovine HBOC that is currently available for Expanded Access use under the FDA's Expanded Access (Compassionate Use) Program. They report the results of 22 clinical trials of phases 1 to 3 where HBOC-201 was administered to human volunteers and patients. Control fluids in these trials included synthetic colloids, crystalloids, and a few with pRBCs. The general conclusion was that HBOC-201 seemed to be well tolerated over a range of doses and the adverse effects were easily managed with no cardiotoxicity and no increase in mortality compared with up to 3 units of pRBCs. Dube et al. (6) further analyzed the data from the HBOC-201 phase 3 trial as well as the PolyHeme trauma trial in an attempt to understand the higher incidence of adverse events in patients who received HBOCs and the ability of these fluids to maintain total hemoglobin (THb) levels. Both papers reached similar conclusions regarding why these HBOCs failed to achieve their clinical goals and that the NIH/FDA decision 10 years ago to halt all clinical testing may have been flawed. Mackenzie et al. (5) include a table of lessons learned to assist clinicians avoid the clinical management errors of volume overload and incomplete treatment of anemia that plagued these previous trials. Hill-Pryor et al. (7) summarize all the HBOC presentations at the DoD State of the Science meeting and provide a historic perspective on HBOC development and some exciting new areas for oxygen therapeutic applications such as in organ transplantation. They also discuss the challenges for clinical trial design that will be faced by next-generation HBOCs, but like the majority of attendees at the meeting, hold the opinion that the previous data are strong enough to support further development of HBOCs but with the indication for when red blood cell transfusion is not an option. Perfluorocarbons are another class of oxygen carriers that can deliver oxygen to tissues, yet are distinctly different molecules than HBOCs. Prepared as an emulsion, PFCs had been used to enhance oxygen delivery in several clinically important conditions of ischemia until questions regarding side effects led the FDA to stop further evaluation in humans. In this Supplement, Spiess (8) provides an overview the chemistry of PFCs, their general characteristics, how they differ from HBOCs, their biological effects to deliver oxygen to ischemic tissue, and the continuing need for such a therapeutic today. Aspects of oxygen transport and the effects of PFCs on blood flow and oxygenation at the microvascular level were reviewed by Torres Filho (9). In vitro and in vivo studies using phosphorescence quenching techniques and noninvasive intravital videomicroscopy observed that different PFCs enhanced oxygen delivery when added to human blood in vitro and improved microcirculatory blood flow and tissue PO2 compared with saline in a rat arterial gas embolism model. His review of the literature also concluded that PFCs have the potential to enhance oxygen delivery and treat hypoxia and ischemia. Graham et al. (10) reviewed a specific PFC, Dodecafluoropentane (DDFPe), with respect to preclinical studies of hemorrhagic shock and traumatic brain injury (TBI). Low-dose DDFPe raised arterial oxygen content in hemorrhaged pigs and improved long-term survival compared with Hextend and improved survival in an acute rat hemorrhage study. It also improved brain tissue oxygen levels in a rat TBI model. Spahn and Keipert (11) present an editorial comment regarding use of perflubron emulsions in two clinical trials of 639 noncardiac surgery patients to enhance oxygen delivery as part of a blood management system to maintain hemoglobin levels above 90 g/L. These authors concluded that PFCs reduced the need for allogeneic blood transfusions in these patients and although platelet counts dropped, no coagulopathic bleeding was observed. They also noted the potential of PFCs to support tissue oxygenation in ischemic states. Hill (12) provides more of an overview of previous PFC formulations and the results of all clinical trials in both cardiac and noncardiac surgery patients with different PFCs. Fluosol-DA was originally approved to enhance oxygen delivery in high-risk cardiac angioplasty, but it became obsolete with development of improved catheters, as well as it being difficult to administer. Taken together with dose restrictions and serious adverse effects, key clinical trials were discontinued. Particular side effects of concern were complement activation and thrombocytopenia (11). The platelet effects of PFCs, as well as effects on inflammation, are reviewed by Spiess (13) in this Supplement. The platelet effect seems time-limited and is not associated with all PFC formulations. In addition, it has not been reported in animal studies. He discusses these effects in context of interest to further development of PFCs for clinical use in trauma patients and also addresses newer emulsifiers being used in newer PFC formulations. To this end, Latson (14) reviews the current knowledge regarding Perfloran, renamed Vidaphor for potential marketing in North America. Originally approved in Russia, it is said to have been administered to over 35,000 patients with evidence of benefit to treat ischemia and with mild and manageable side effects, possibly related to its small particle size. Perfloran is similar to perflubron but uses a different emulsifier. Certainly additional research will be needed to confirm the Russian findings. With renewed interest by the military to encourage further development of these products for resuscitation from traumatic injury, it is emphasized that these products should be considered when pRBCs or whole blood is not available or not an option, rather than as “blood substitutes” (15) as they were originally envisioned. The assessment of the previous clinical trials, mentioned above, clearly indicate that trial design will be key to obtaining regulatory approval of these products. In this Supplement, Shupp et al. (16) describe the development of a robust protocol to assess the natural history of coagulation dysfunctions in trauma patients in a multicenter systems biology approach. The key was development of a comprehensive Manual of Operations (MOO) that was applied at all centers. It is proposed that such an interdisciplinary process to develop a robust protocol, along with the MOO, can serve as a template for future clinical trials in critically ill patients that could be instrumental in further evaluation of next-generation HBOCs and PFCs for regulatory approval. As noted by Pusateri et al. (15), the South African experience have demonstrated that HBOCs can be used safely and effectively, when RBCs are not an option. These authors echo the consensus of the meeting that HBOCs and PFCs should be reevaluated as a temporary bridge to improve oxygen delivery to tissues when blood is unavailable or not an option (7, 15). Overall, all the authors agree that this could be a viable path for the long-awaited regulatory approval of these compounds. The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.
No takes yet. Share an insight, caveat, or question.
Michael A. Dubick (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: